Opioid Risk Assessment Tools in Chronic Low Back Pain
Before initiating opioid therapy in your 54-year-old patient with chronic low back pain, you should use a validated risk assessment tool like the SOAPP-R (Screener and Opioid Assessment for Patients with Pain-Revised) at baseline, and the results should directly inform whether to prescribe opioids at all, what dose to start, and how frequently to monitor.
When to Use Risk Assessment Tools
Risk assessment must occur before starting opioid therapy and should be integrated into your initial evaluation 1. The CDC guidelines explicitly recommend evaluating risk factors for opioid-related harms before initiating therapy and incorporating risk mitigation strategies into your management plan 1. This is not optional—it's a core component of safe opioid prescribing.
For your patient specifically:
- Timing: Administer the SOAPP-R during the visit when you're considering opioid initiation
- Context: This comes after confirming that non-opioid treatments (NSAIDs, acetaminophen, physical therapy, cognitive behavioral therapy) have been exhausted 2, 3
- Integration: Use alongside checking your state's Prescription Drug Monitoring Program (PDMP) and baseline urine drug screening 1
How Results Should Guide Prescribing
High-Risk Patients (SOAPP-R ≥18)
If your patient scores ≥18 on the SOAPP-R 4:
Consider NOT prescribing opioids at all. The evidence shows opioids provide only modest short-term benefits for chronic low back pain with questionable long-term efficacy 2, 5, and high-risk patients face substantially increased risks of aberrant drug-related behaviors, addiction, and overdose 2, 1.
If you still proceed with opioids despite high risk:
- Start with the absolute lowest dose of immediate-release (not extended-release) opioids 1
- Keep doses well below 50 MME/day 1
- Schedule follow-up within 1-2 weeks (not the standard 1-4 weeks) 1
- Check PDMP at every prescription 1
- Conduct urine drug testing monthly initially, then at least every 3 months 1
- Prescribe naloxone for overdose reversal 1
- Set a time-limited trial (e.g., 4-6 weeks) with predetermined functional goals 2, 1
Low-Risk Patients (SOAPP-R <18)
Even in lower-risk patients 4:
- Start immediate-release opioids at the lowest effective dose 1
- Avoid doses ≥50 MME/day; carefully justify any decision to approach 90 MME/day 1
- Follow-up within 1-4 weeks to reassess benefits versus harms 1
- Check PDMP at initiation and periodically (ranging from every prescription to every 3 months) 1
- Urine drug testing before starting and at least annually 1
- Reassess every 3 months whether benefits outweigh harms 1
Specific Risk Factors to Identify
The SOAPP-R assesses multiple domains 6, 4, but pay particular attention to:
- History of substance abuse (alcohol, illicit drugs, prescription medications)
- Mental health conditions (depression, anxiety)—these predict higher opioid prescribing 7
- Legal problems related to substance use
- Medication-seeking behaviors or craving patterns
- Heavy tobacco use
- Younger age (associated with higher risk) 8
- Concurrent benzodiazepine use (absolute contraindication to combine with opioids) 1
Critical Caveats
The SOAPP-R has limitations: It shows good sensitivity (0.81) but modest specificity (0.68) 4, meaning some patients will be incorrectly flagged as high-risk. However, given the serious harms of opioid misuse versus the modest benefits for chronic low back pain 2, 5, err on the side of caution.
Risk assessment is ongoing, not one-time: Even low-risk patients can develop problems. Continue monitoring with tools like the Current Opioid Misuse Measure (COMM) at follow-up visits 9.
Risk tools don't replace clinical judgment: If your patient has exhausted truly comprehensive non-opioid therapy (including supervised exercise, cognitive behavioral therapy, and potentially multidisciplinary pain programs 3), and shows clear functional impairment, the risk assessment helps you prescribe more safely—but the fundamental question remains whether opioids are appropriate at all for chronic low back pain given their limited long-term efficacy 2, 5.
Document everything: Record the SOAPP-R score, your risk-benefit discussion with the patient, realistic treatment goals, and your plan for discontinuation if benefits don't materialize 1.